Hemorrhagic Shock Clinical Trial
— RESCUE-ShockOfficial title:
Resuscitative Endocrinology: (RESCUE - Shock): A Phase II Trial to Evaluate the Effects of Single Dose Intravenous Premarin for Treatment of Patients With Hemorrhagic Shock
NCT number | NCT00973102 |
Other study ID # | RESCUE - Shock |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | July 2009 |
Est. completion date | May 2012 |
Verified date | March 2020 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Based on encouraging results from animal studies, the investigators hypothesize that early administration of IV Premarin® in patients with hemorrhagic shock will safely reduce secondary injury, and improve survival.
Status | Completed |
Enrollment | 50 |
Est. completion date | May 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Age= 18 yrs or < 50 yrs 2. Blunt or penetrating trauma leading to presumed hemorrhagic shock 3. Pre-hospital or ED systolic blood pressure < 90 4. Receiving medical treatment in the Emergency Department (ED) of Parkland Hospital or Baylor University Medical Center Emergency Department, Level I Trauma Centers in Dallas, Texas Exclusion Criteria: 1. Those who would receive the study drug > 120 minutes after the traumatic event 2. Time of injury is unknown 3. Known indication for IV estrogen 4. Known contraindication for estrogen 5. Estimated age <18 or > 50 years 6. Cardiopulmonary Resuscitation (CPR) prior to randomization 7. Known incarceration 8. Severe hypothermia (suspected T < 28° C) 9. Drowning or asphyxia due to hanging 10. Burns total body surface area (TBSA) > 20% 11. Isolated penetrating injury to the head 12. Known inclusion in another interventional trial related to this traumatic event prior to randomization 13. Known legal do not resuscitate (DNR) orders in place prior to randomization 14. Recognized spinal cord injury prior to study drug administration |
Country | Name | City | State |
---|---|---|---|
United States | Baylor University Medical Center | Dallas | Texas |
United States | Parkland Hospital | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center | Resuscitation Outcomes Consortium, University of Washington |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival | Survival is defined as the number of patients who were discharged from the hospital alive prior to 28 days post injury or the number of patients still alive in the hospital 28 days post injury. The trial examines the rate of enrolled patients on each arm who survived to 28 days. | 28 Days | |
Secondary | Acute Respiratory Distress Syndrome (ARDS) Free Survival | ARDS is a life-threatening condition characterized by inflammation of the lungs. The trial measures the number of days alive and without ARDS within 28 days post injury. Patients who die within 28 days are given value of 0, similarly, patients who live 28 days but have ARDS for all 28 days. A higher score (greater days) indicates better prognosis. Exudative stage is 0-6 days, proliferative stage is 7-10 days, Fibrotic stage is >10-14 days. | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04149171 -
Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage
|
Phase 3 | |
Not yet recruiting |
NCT06070350 -
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
|
Phase 3 | |
Not yet recruiting |
NCT02880163 -
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
|
N/A | |
Completed |
NCT02924792 -
Sternal Intraosseous Transfusion of Autologous Whole Blood: A Comparison of Flow Rates and Degree of Hemolysis
|
N/A | |
Terminated |
NCT00750997 -
Hypertonic Modulation of Inflammation Following Injury
|
N/A | |
Terminated |
NCT03477006 -
Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial
|
Phase 3 | |
Not yet recruiting |
NCT04987411 -
Detection of Exhaled Methane Levels in Hemorrhagic Shock
|
||
Recruiting |
NCT04610814 -
Blood Transfusion by Boston MedFlight Registry
|
||
Completed |
NCT02071290 -
Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock
|
N/A | |
Completed |
NCT03535441 -
HMGB1 Release From Hemorrhagic Shock Patients
|
||
Completed |
NCT03480555 -
Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients
|
N/A | |
Completed |
NCT03402035 -
Shock, Whole Blood, and Assessment of TBI S.W.A.T. (LITES TO 2)
|
||
Completed |
NCT05081063 -
Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
|
Phase 3 | |
Recruiting |
NCT03235921 -
Use of Nitroglycerine to Improve Signs of Poor Peripheral Perfusion in Patients With Traumatic Hemorrhagic Shock
|
Phase 2 | |
Active, not recruiting |
NCT03469947 -
California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA
|
Phase 3 | |
Completed |
NCT01411852 -
Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma
|
Phase 2 | |
Withdrawn |
NCT01221389 -
Study Using Plasma for Patients Requiring Emergency Surgery
|
Phase 4 | |
Recruiting |
NCT03406598 -
Bedside Visual Analysis of Sublingual Microcirculation in Shock Patients
|
||
Completed |
NCT00328133 -
The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry
|
N/A | |
Completed |
NCT00379522 -
Vasopressin in Traumatic Hemorrhagic Shock Study
|
Phase 2/Phase 3 |